There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ligand Pharma (LGND – Research Report) and Johnson & Johnson (JNJ – Research Report) with bullish sentiments.
Johnson & Johnson (JNJ)
In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Johnson & Johnson, with a price target of $178.00. The company’s shares closed last Wednesday at $154.06, close to its 52-week low of $150.11.
According to TipRanks.com, Chadha has 0 stars on 0-5 stars ranking scale with an average return of
Johnson & Johnson has an analyst consensus of Moderate Buy, with a price target consensus of $177.58, a 14.3% upside from current levels. In a report issued on October 2, Cantor Fitzgerald also maintained a Buy rating on the stock with a $215.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LGND:
